Ypsomed supplies Bigfoot Biomedical with infusion sets
Burgdorf, 24.10.2017, 7.00 a.m. – Ypsomed and the US Bigfoot Biomedical company today announced their agreement for a partnership. Ypsomed will supply Bigfoot Biomedical with a modified, patented version of the Orbit infusion set. This will be used by Bigfoot in their clinical study on automated insulin therapy in people with diabetes. Based in California, Bigfoot Biomedical develops novel technologies for the automation of insulin therapies with a focus on everyday suitability and simple operation for the users of its products, same as Ypsomed. Bigfoot Biomedical decided in favour of Ypsomed's Orbit infusion set for the significant study of its insulin pump system. "The Orbit infusion sets are extremely well thought out. By offering our study participants an infusion set which is flexible, reliable and easy to use, we can significantly reduce the burden of diabetes therapy" is how Jeffrey Brewer, President and CEO of Bigfoot Biomedical, describes the new partnership.
"Both Ypsomed and Bigfoot Biomedical are dedicated to the development of products which simplify the everyday management of diabetes for those affected. Our partnership is an example of how consistently both companies follow this objective" says Simon Michel, CEO of Ypsomed. "This cooperation gives us the opportunity of offering our popular Orbit infusion sets to even more people with diabetes."
The Ypsomed Orbit infusion sets can be rotated through 360° and give the users greater freedom of movement. Furthermore, they are easy to place and are fitted with a heat-activated patch for secure adhesion to the skin. TheOrbit infusion sets are available with steel or soft cannulas, depending on the preferences of the user. Ypsomed will also provide Bigfoot Biomedical with a handy inserter for their study.
Bigfoot Biomedical completed its first clinical study for their new automated solution for insulin delivery at the end of 2016 and plans to start the pivotal study with the Orbit infusion sets in 2018 in the United States.
For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG.
Contact:Thomas Kutt
Head of Investor Relations
Ypsomed Holding AG
Phone +41 34 424 35 55
Send emailDownloads: About the Ypsomed GroupThe Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1’400 employees. Additional information is available under
www.ypsomed.com.
About Bigfoot Biomedical, Inc.Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes and, with its Loop and Inject services, seeks to change the paradigm of care for insulin-requiring diabetes by leveraging data, connectivity, automation, and machine learning to reduce the burden on people with insulin-requiring diabetes and maximize the leverage of health care providers. Learn more at
bigfootbiomedical.com.
